SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STDY
CUSIPN/A
Phone925-272-4999
Debt
Debt-to-Equity RatioN/A
Current Ratio4.80
Quick Ratio4.80
Price-To-Earnings
Trailing P/E Ratio-10.99
Forward P/E Ratio-6.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales118.08
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book29.53
Profitability
EPS (Most Recent Fiscal Year)($0.43)
Net Income$-23,200,000.00
Net Margins-2,177.00%
Return on Equity-94.69%
Return on Assets-47.15%
Miscellaneous
Employees26
Outstanding Shares26,740,000
Market Cap$126.36 million
Steadymed (NASDAQ:STDY) Frequently Asked Questions
What is Steadymed's stock symbol?
Steadymed trades on the NASDAQ under the ticker symbol "STDY."
How were Steadymed's earnings last quarter?
Steadymed Ltd (NASDAQ:STDY) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.17. Steadymed had a negative return on equity of 94.69% and a negative net margin of 2,177.00%. View Steadymed's Earnings History.
When is Steadymed's next earnings date?
What is the consensus analysts' recommendation for Steadymed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steadymed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Steadymed.
Who are some of Steadymed's key competitors?
Some companies that are related to Steadymed include Akebia Therapeutics (AKBA), Zymeworks (ZYME), Evolus (EOLS), Five Prime Therapeutics (FPRX), Collegium Pharmaceutical (COLL), Minerva Neurosciences (NERV), Progenics Pharmaceuticals (PGNX), Kindred Biosciences (KIN), TG Therapeutics (TGTX), Forty Seven (FTSV), Depomed (DEPO), Dermira (DERM), ZIOPHARM Oncology (ZIOP), Aclaris Therapeutics (ACRS) and Merus (MRUS).
Who are Steadymed's key executives?
Steadymed's management team includes the folowing people:
- Mr. Jonathan M. N. Rigby, Pres, CEO & Director (Age 50)
- Mr. David W. Nassif, Exec. VP & CFO (Age 64)
- Mr. Robert Zwolinski, Sr. VP of Operations
- Ms. Marylyn Rigby, Sr. Director of Investor Relations and Marketing
- Mr. Carl Hicks Jr., Editor & Chief of Bephenomental.com
When did Steadymed IPO?
(STDY) raised $56 million in an initial public offering on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Steadymed?
Shares of STDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steadymed's stock price today?
One share of STDY stock can currently be purchased for approximately $4.7250.
How big of a company is Steadymed?
Steadymed has a market capitalization of $126.36 million and generates $1.07 million in revenue each year. The company earns $-23,200,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Steadymed employs 26 workers across the globe.
What is Steadymed's official website?
How can I contact Steadymed?
Steadymed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected]
MarketBeat Community Rating for Steadymed (NASDAQ STDY)
MarketBeat's community ratings are surveys of what our community members think about Steadymed and other stocks. Vote "Outperform" if you believe STDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
